Android Apple

Replimune Shares Top 52-Week High After Submitting Application for Melanoma Treatment

By MarketWatch   |   1 month ago
Replimune Shares Top 52-Week High After Submitting Application for Melanoma Treatment

Replimune Group's stock surged to a 52-week high in after-hours trading after receiving breakthrough therapy designation for RP1 and submitting a biologics license application. The stock jumped 22% to $13.50, closing at $11.05 in the regular session.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.